.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Prof. Dr. med Johannes Oldenburg

Chair

23/09/2022
13:30 – 15:00
Vortragssitzung
Joint GTH
Arnold Schönberg

Speaker

21/09/2022
15:40 – 15:50 6 Min. 4 Min.
Abstractvortrag
VS-7-4
Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: Results from the GENEr8-1 two-year analysis
10. Hämostaseologie – Koagulopathien, Plasmaderivate und Hämophilie, 12. Zelltherapie und Gentherapie
22/09/2022
17:15 – 17:20 3 Min. 2 Min.
Poster
PS-4-12
Interim 52-Week Analysis of Immunogenicity to the Vector Capsid and Transgene-Expressed Human FVIII in GENEr8-1, a Phase 3 Clinical Study of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A
10. Hämostaseologie – Koagulopathien, Plasmaderivate und Hämophilie, 12. Zelltherapie und Gentherapie

Further involvements

21/09/2022
15:30 – 15:40 6 Min. 4 Min.
Abstractvortrag
VS-7-3
Structural investigations into coagulation factor VIII full-length and B domain
10. Hämostaseologie – Koagulopathien, Plasmaderivate und Hämophilie, 9. Hämotherapie
21/09/2022
15:40 – 15:50 6 Min. 4 Min.
Abstractvortrag
VS-7-4
Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: Results from the GENEr8-1 two-year analysis
10. Hämostaseologie – Koagulopathien, Plasmaderivate und Hämophilie, 12. Zelltherapie und Gentherapie
22/09/2022
17:15 – 17:20 3 Min. 2 Min.
Poster
PS-4-12
Interim 52-Week Analysis of Immunogenicity to the Vector Capsid and Transgene-Expressed Human FVIII in GENEr8-1, a Phase 3 Clinical Study of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A
10. Hämostaseologie – Koagulopathien, Plasmaderivate und Hämophilie, 12. Zelltherapie und Gentherapie
22/09/2022
17:20 – 17:25 3 Min. 2 Min.
Poster
PS-3-11
Rivaroxaban levels in plasma show greater inter-individual variation than apixaban levels in treatment of venous thromboembolism
10. Hämostaseologie – Koagulopathien, Plasmaderivate und Hämophilie, 9. Hämotherapie
22/09/2022
17:35 – 17:40 3 Min. 2 Min.
Poster
PS-3-14
Effect of GABARAP protein on the intracellular distribution of FVIII
10. Hämostaseologie – Koagulopathien, Plasmaderivate und Hämophilie
22/09/2022
17:45 – 17:50 3 Min. 2 Min.
Poster
PS-3-16
Whole genome expression analysis resolves the correlation between genetic knockout of single genes and the obtained phenotype in relation to FVIII secretion
10. Hämostaseologie – Koagulopathien, Plasmaderivate und Hämophilie